AiON
← Medical directoryActive ingredient

Kayshild (semaglutide)

Brand name for once-weekly semaglutide 2.4 mg, which has held conditional marketing authorisation in the EU since 26 March 2026 for non-cirrhotic MASH with F2–F3 fibrosis, alongside diet and exercise. It is a GLP-1 agonist.

Institutional endorsement by Clínica Evolution

This entry is for information. Your case requires an individual medical assessment.